Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab With Trastuzumab and Pertuzumab in HER2-Addicted Breast Cancer
NCT07772245Phase 2Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 2 trial of retifanlimab in breast cancer. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
retifanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07772245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772245.